Overview

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

This is a phase 2 trial investigating the effect and safety of pembrolizumab and photodynamic therapy (PDT) in metastatic esophageal squamous cell carcinoma failed at least one line of systemic treatment. The primary efficacy hypotheses are that the objective response rate (ORR) of combination of PDT and pembrolizumab could be improved compared with pembrolizumab for both primary and metastatic lesions.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University

Treatments:

Pembrolizumab